SEERS mobiCARE ECG Monitor Gains Health Canada Approval
South Korean diagnostic firm SEERS received a Class II Medical Device Licence from Health Canada for its AI-powered mobiCARE wearable electrocardiogram solution. This approval, following US FDA clearance, enables the company to commercialize its device across North America.
Regulatory Clearance Opens North American Market
South Korean diagnostic company SEERS has obtained a Class II Medical Device Licence (MDL) from Health Canada for its AI-powered mobiCARE wearable electrocardiogram (ECG) analysis solution. Health Canada granted the licence last Thursday, following an application submitted on June 26. This regulatory process concluded in just over two months.
The approval covers the complete mobiCARE system, including its wearable ECG device, electrodes, and associated software for both healthcare providers and patients. This Canadian clearance follows the U.S. Food and Drug Administration (FDA) 510(k) clearance, which SEERS received in June this year. Together, these approvals provide SEERS with regulatory clearance across both the United States and Canada.
mobiCARE's Function and Korean Market Performance
SEERS states its mobiCARE solution allows patients to undergo ECG monitoring during their daily activities. The system uses AI-based algorithms to analyze collected data, which SEERS claims supports arrhythmia diagnosis. According to SEERS, mobiCARE is the most widely used product in Korea's wearable ECG monitoring market.
The company reports its solution is currently deployed in over 1,100 medical institutions within Korea. SEERS also states that mobiCARE has facilitated more than 770,000 tests and accumulated over 39 million hours of ECG analysis data.
Commercialization Strategy Targets North America
The recent regulatory approvals establish a foundation for SEERS's commercialization efforts across North America. The company's overseas strategy centers on expanding mobiCARE, leveraging its platform validated in Korea, rather than developing distinct products for other markets.
SEERS plans to adapt its existing system to individual market healthcare and reimbursement structures. In the U.S., SEERS is preparing a diagnostic testing service that combines local diagnostic networks with Medicare reimbursement.
Canada also offers public reimbursement for extended ECG monitoring, and SEERS intends to use the new approval to develop commercial models with local healthcare institutions and partners.
SEERS CEO Lee Young-shin states that with the U.S. FDA clearance, its entry into the UAE market, and now Canadian approval, mobiCARE's global business will enter a full commercialization phase in the second half of this year.
Outlook for Asian Health Tech Expansion
Lee Young-shin states the company aims to generate business results in North America and the Middle East, positioning overseas sales as a new growth driver. This move by SEERS demonstrates a strategy for Asian health technology companies to expand into Western markets by securing necessary regulatory approvals and adapting to local reimbursement models.
For other Korean firms in medical devices or health-adjacent beauty tech, SEERS's approach highlights the importance of leveraging domestic validation and adapting platforms for international market entry. This includes navigating complex reimbursement systems to ensure commercial viability beyond initial market access.
Three newsletters, one newsroom.
The Beauty Brief delivers Asia's beauty week every Monday. Regulatory Radar tracks the rule changes that move markets. Trend Pulse decodes what consumers want next. All free to start.
